

1 **Significance of neutrophil-to-lymphocyte ratio,**
2 **platelet-to-lymphocyte ratio for predicting clinical outcomes in**
3 **COVID-19**

4 Shaoping Huang¹, Min Liu¹, Xiaolu Li², Zhiyin Shang¹, Ting Zhang^{2*},
5 Hongzhou Lu^{1*}

6
7 **Author Affiliations:** ¹Shanghai Public Health Clinical Center, Fudan University,
8 Shanghai 201508, China; ² Department of Gastroenterology, Hepatology, and
9 Nutrition, Shanghai Children’s Hospital, Shanghai Jiao Tong University, Shanghai
10 200062, China

11 **Abstract**

12 **Background:** The epidemic of 2019 novel coronavirus (COVID-19) struck China in
13 late December, 2019, resulting in about 200000 deaths all over the world. Numerous
14 observational studies have suggested that the neutrophil-to-lymphocyte ratio (NLR)
15 and lymphocyte proportion and the platelet-to-lymphocyte ratio (PLR) are
16 inflammatory markers. Our study aimed to detect the role of NLR, PLR in predicting
17 the prognosis of COVID-19.

18 **Methods:** Four hundred and fifteen consecutive patients were enrolled in Shanghai
19 Public Health Clinical Center affiliated to Fudan University, between 20 January and
20 11 April 2020 with confirmed COVID-19. Epidemiology, symptoms, signs, and
21 laboratory examinations during the hospital stay were collected and compared
22 between non-severe and severe patients. Statistical analysis was performed by SPSS
23 25.0 software.

24 **Results:** Four hundred and fifteen laboratory-confirmed COVID-19 patients were
25 included in our study, among which 386 (93%) patients were not severe, and 27 (7%)
26 were severe. The proportion of males in severe cases is higher than in non-severe
27 cases (75.86% vs. 50.52%, P=0.008). The age between the two groups is different

28 (P=0.022). Compared with non-severe patients, severe patients exhibited more

29 comorbidities, including hypertension (48.28% vs. 19.43%, $p<0.001$), diabetes
30 (20.69% vs. 6.99%, $p=0.009$), chronic obstructive pulmonary disease (51.72% vs.
31 6.22%, $p<0.001$), and fatty liver (37.93% vs. 15.8%, $p=0.002$), respectively. NLR and
32 PLR showed significant difference ($p<0.001$). Diabetes (OR 0.28; 95% CI
33 15.824-187.186), fatty liver (OR 21.469; 95% CI 2.306-199.872), coronary heart
34 disease (OR 18.157; 95% CI 2.085-158.083), NLR (OR 1.729; 95% CI 1.050-2.847)
35 were significantly associated with severe cases with COVID-19. The NLR of patients
36 in severe group had a 1.729-fold higher than that of no-severe group (OR 1.729; 95%
37 CI 1.050-2.847, $P=0.031$).

38 **Conclusions:** NLR is an independent risk factor of severe COVID-19 patients. PLR,
39 NLR were significantly different between severe and non-severe patients, so
40 assessment of NLR, PLR may help identify high risk cases with COVID-19.

41 **Key words:** Neutrophil-to-lymphocyte ratio, Platelet-to-lymphocyte ratio, COVID-19,
42 Severity

43 **Introduction**

44 The epidemic of 2019 novel coronavirus (COVID-19) struck China in late
45 December, 2019. A novel coronavirus was then identified as the causative agent.
46 Many countries and territories have been affected within two months[1-3]. As of April
47 26, 2020, nearly 3,000,000 confirmed cases of COVID-19 occurred, resulting in about
48 200000 deaths. Many cases were mild to moderate with common symptoms at onset
49 of illness, including fever, cough, and fatigue or myalgia. Organ dysfunction included
50 acute respiratory distress syndrome (ARDS), acute liver injury, acute cardiac injury,
51 acute kidney injury, and death could occur in the severe cases[4]. In our study, we
52 focused on patients with COVID-19 in Shanghai, describing the clinical
53 characteristics and prognostic factors.

54 Blood cell interactions are essential in the pathophysiology of inflammation,
55 immune responses, hemostasis, and oncogenesis. Numerous observational studies
56 have suggested that the neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to
57 monocyte ratio (LMR), lymphocyte proportion and the platelet-to-lymphocyte ratio
58 (PLR) are inflammatory markers of immune-mediated, metabolic, prothrombotic, and

59 neoplastic diseases, and are widely investigated as useful predictors for prognosis in
60 many diseases[5-7]. These interactions are multifaceted, and it is often difficult to
61 distinguish primary triggering signals and the specific roles of each cell type in the
62 development and progression of disease states. Recent researches of COVID-19
63 indicated severe patients tended to have higher NLR[8, 9]. Our study aimed to detect
64 the role of NLR, PLR, LMR in predicting the prognosis of COVID-19.

65 **Material and Methods**

66 **1.Study Cohort and Design**

67 We recruited 415 consecutive patients in Shanghai Public Health Clinical Center
68 affiliated to Fudan University (the designated hospital in the Shanghai area), between
69 20 January and 11 April 2020 with confirmed COVID-19. Epidemiology, symptoms,
70 signs, laboratory examinations, chest computerized tomography (CT) scan, and
71 treatment options during the hospital stay were all collected and compared between
72 non-severe and severe patients. This study was approved by the Medical Ethics
73 Committee of Shanghai Public Health Clinical Center affiliated to Fudan University.

74 **2. Statistical Analysis**

75 Statistical analysis was performed by SPSS 25.0 software. All data of the
76 demographic and clinical characteristics were expressed as frequencies and
77 proportions for categorical variables, mean SD or median and interquartile (IQR) for
78 continuous variables. We used the one-way ANOVA for categorical variables and the
79 Mann–Whitney U test for continuous variables. To look at risk factors of severe
80 COVID-19, laboratory values were compared with non-severe and severe patients.
81 Then binary logistic regression analysis was used to analyze the risk factors. A P value
82 of <0.05 was considered to be statistically significant.

83 **Results**

84 **1. Demographic and Epidemiological features**

85 415 laboratory-confirmed COVID-19 patients were enrolled in our study, among
86 which 386 (93%) patients were not severe, and 27 (7%) were severe. The
87 demographic, and epidemiologic features on admission were shown in Table1. Most
88 patients were ethnic Chinese (393/415, 94.7%). The median age of patients was 44

89 years (IQR 30-61), ranged from 15 years to 84 years. About a half (217, 52.3%) of all
90 patients were male. 220 (53%) patients developed COVID-19 due to contacting with
91 Wuhan, Hubei Province, and 27(6.5%) were imported cases.

92 **2. Clinical characteristics**

93 As showed in Table 2, the proportion of males in severe cases is higher than in
94 non-severe cases (75.86% vs. 50.52%, $P=0.008$). The age between the two groups is
95 different ($p=0.022$). Compared with non-severe patients, severe patients exhibited
96 more comorbidities, including hypertension (48.28% vs. 19.43%, $p<0.001$), diabetes
97 (20.69% vs. 6.99%, $p=0.009$), chronic obstructive pulmonary disease (51.72% vs.
98 6.22%, $p<0.001$), and fatty liver (37.93% vs. 15.8%, $p=0.002$), respectively. Only one
99 patient had HIV infection. 22(5.3%) patients had HBV infection and no significant
100 difference was found between non-severe and severe cases. Among all these cases,
101 95.34% of the non-severe group were not smokers, which is similar with severe group
102 of 89.66%. Only 3.11% of non-severe cases had drinking history, and the severe cases
103 of 6.9%. For the virus clearance, there were 15 patients (3.89%) showed that the
104 intestinal clearance is later than that of the respiratory.

105 Patients with COVID-19 were treated with different drugs. From our data,
106 patients with severe COVID-19 treated with antiviral medications, interferon
107 atomization, antibiotics, blood product, systemic corticosteroids, and low molecular
108 weight heparin, which were significantly higher rate than that in the patients with
109 no-severe COVID-19 ($P<0.05$).

110 **3. Laboratory Findings**

111 The laboratory findings were summarized in Table 3 and Table 4. Many patients
112 had hematologic abnormalities on admission: anemia (hemoglobin level < 120 g/L) in
113 13.5% of patients, leukopenia (leukocyte count $< 4 \times 10^9$ cells/L) in 23.9%,
114 lymphopenia (lymphocyte count $< 1 \times 10^9$ cells/L) in 38.8% , and high monocyte
115 percentage ($>10\%$) in 11.5%. The prothrombin time was prolonged (>14 seconds) in
116 the 5.8% of patients. Alanine aminotransferase (>40 U/L) were exhibited in 17.5% of
117 the patients, and 54.3% of the patients had elevated C-reactive protein levels (>6
118 mg/L).

119 Our study discovered that the white blood cell (WBC) counts on admission of the
120 severe and non-severe cases had no significant difference ($P=0.082$). Neutrophil
121 counts were significantly higher in severe cases than non-severe cases ($P<0.05$).
122 Whereas lymphocyte counts were significantly lower in severe cases ($0.88 \times 10^9/L$)
123 than non-severe cases ($1.12 \times 10^9/L$). The monocyte percentage was also different
124 between the 2 groups ($P=0.015$). Severe patients had lower hemoglobin level than that
125 of non-severe patients ($P=0.017$). NLR, LMR and PLR were compared with severe
126 and non-severe cases, among which NLR and PLR were significant different
127 ($P<0.001$).

128 Compared with non-severe cases, inflammation-related marker levels (CRP, ESR)
129 were significantly higher in severe cases ($P<0.05$). The levels of procalcitonin,
130 NT-proB-type natriuretic peptide (NT-proBNP), d-dimer, FDP, albumin, lactate
131 dehydrogenase (LDH), total bilirubin, conjugated bilirubin, CK-MB were elevated in
132 all patients, and significant difference was found between non-severe and severe
133 groups ($P<0.05$).

134 **4. Analysis with LDH, NLR, LMR and PLR**

135 To further define the value of the inflammatory-related parameters in predicting
136 clinical outcomes in COVID-19 patients, the optimal cut-off values for preoperative
137 LDH, NLR, LMR, and PLR that best predicted were calculated as followed: 290.5
138 (area under the curve (AUC): 0.728; sensitivity: 65.5%; specificity: 88.8%), 3.5 (AUC:
139 0.764; sensitivity: 72.4%; specificity: 75.1%), 3.0 (AUC: 0.608; sensitivity: 70.0%;
140 specificity: 63.9%), and 222.5 (AUC: 0.659; sensitivity: 48.3%; specificity: 82.6%),
141 respectively (Fig. 1A-D). Then, the patients were dichotomized into high or low
142 LDH/NLR/PLR/LMR groups with these cut-off values. We found that there were
143 significant differences in LDH, NLR and PLR between severe and non-severe groups.
144 ($P<0.001$).

145 **5. Risk factors for severe cases**

146 In the logistic regression model, variables such as diabetes (OR 0.28; 95% CI
147 15.824-187.186), fatty liver (OR 21.469; 95% CI 2.306-199.872), coronary heart
148 disease (OR 18.157; 95% CI 2.085-158.083), NLR (OR 1.729; 95% CI 1.050-2.847)

149 were significantly associated with severe cases with COVID-19, while ESR is a
150 protective factor (OR 0.949; 95% CI 0.940-0.999) for no-severe patients (Table 5).
151 The forecast accuracy is 96.6%.

152 In order to better diagnose severe COVID-19, we use the ROC curves to
153 calculate the optimal cut-off values for the combined predictive indicator and other
154 risk factors (Figure 2). The combined predictive indicator which is formulated by
155 logistic regression models, is superior to any single indicator in predicting severe
156 patients.

157 **Discussion**

158 Nowadays, COVID-19 outbreak has caused widespread concern and threatened
159 the global public health security. This retrospective cohort study included 415
160 COVID-19 patients, among which 29 (7%) were severe. This is different from reports
161 from Wuhan, China[2, 10]. The clinical, laboratory, and radiographic features in this
162 cohort of patients with COVID-19 in Shanghai were nonspecific and similar to those
163 in other series[1-4, 11, 12]. Recently, the epidemics has transmitted from the first
164 stage, in which imported cases composed of the main laboratory-confirmed cases in
165 Shanghai. Compared with patients who had non-severe COVID-19, patients with
166 severe COVID-19 had lower lymphocyte percentage, lymphocyte counts, monocyte
167 percentage, and higher neutrophil percentage, neutrophil counts at presentation. These
168 patients may have had a higher viral load at presentation, which may have led to the
169 apparently worse of laboratory values. We also compared NLR and PLR, the two
170 groups have significantly differences. This probably due to their viral load and
171 immune state. Lactate dehydrogenase, C-reactive protein (CRP), and D-dimer,
172 prothrombin time, FDP, BNP were higher in severe groups than in non-severe groups.
173 From Guang Chen's research, they found that the SARS-CoV-2 infection may affect
174 primarily T lymphocytes particularly CD4+T and CD8+ T cells, resulting in decrease
175 in all numbers as well as IFN- γ production[11]. Our data analyzed these immune
176 markers in order to find the cause of severity of COVID-19.

177 In this cohort, we observed that 66.0% of the patients had at least one underlying
178 disorder (i.e., hypertension, diabetes, coronary heart disease), and a higher percentage

179 of hypertension and fatty liver in the severe cases than the non-severe individuals, in
180 consistent with other studies[12, 13] .The risk factors for severity included age, high
181 LDH level, and high d-dimer level in previous reports[8]. However, different from the
182 findings of previous studies, we found coronary heart disease and fatty liver were the
183 comorbidity associated with the severity of COVID-19.

184 The NLR was higher in severe cases than in non-severe cases which is consistent
185 with recent studies[8, 9]. Besides, we found PLR was also higher in severe patients
186 compared with non-severe patients. Numerous observational studies have suggested
187 that the NLR, LMR, lymphocyte proportion and the PLR are inflammatory markers of
188 immune-mediated, metabolic, prothrombotic, and neoplastic diseases, and are widely
189 investigated as useful predictors for prognosis in many diseases[5-7]. The results of
190 this study have several clinical implications and strengths. Since NLR and PLR could
191 be quickly calculated based on a blood routine test on admission, so we should pay
192 attention to these laboratory findings to identify high risk COVID-19 patients.

193 Recent researches focus on asymptomatic infection[14, 15], possible fecal-oral
194 transmission in SARS-Cov-2 infection[16], and positive result for SARS-Cov-2 test
195 in recovered patients[17]. At the same time, some reports discussed some COVID-19
196 patients with underlying disorders, such as diabetes[18], cancer[19] and so on. As we
197 all know, people around the world should pay attention to this disease.

198 There are some limitations in our study. First, the number of observed events is
199 to some extent small which may limit the statistical power of this research. However,
200 the sample size is sufficient to draw a conclusion. Second, in our group, there were
201 fewer severe patients which may not balance for analysis. Third, the causal
202 relationship between abnormal laboratory findings and severity could not be estimated
203 since laboratory findings were measured on admission and may not indicate the
204 severity of COVID-19.

205

206

207

208

209

210

211

212 **Table 1. Demographic and Epidemiologic Characteristics of Patients**

213 **with COVID-19**

214

Characteristics	All patients, (n=415)	Patients with non-severe COVID-19 (n=386)	Patients with severe COVID-19 (n=29)
Demographic			
Median age (range), <i>y</i>	44(30-61)	41(30-59)	64.5(62.25-74.75)
Men/women, <i>n/n</i>	217/198	195/191	22/7
BMI	23.61(21.24-25.95)	23.51(21.13-25.95)	24.22(22.45-27.54)
Ethnicity, <i>n</i>			
Ethnic Chinese	393	364	29
Non-Chinese	22	22	0
Recent travel to areas with COVID-19 outbreak, <i>n</i>			
Hubei Province	220	204	16
Wenzhou, Zhejiang Province	2	2	0
Outside China	27	26	1

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235
236
237
238
239
240

Table 2. Clinical Features of Patients with COVID-19

Variables	Patients with non-severe COVID-19 (n= 386)	Patients with severe COVID-19 (n=29)	P value
Gender			
Male	195(50.52%)	22(75.86%)	0.008
Female	191(49.48%)	7(24.14%)	
Age, years			
0-44	221(57.25%)	10(34.48%)	0.022
45-64	118(30.57%)	16(55.17%)	
≥65	47(12.18%)	3(10.34%)	
Underlying diseases, n (%)			
Hypertension			
No	311(80.57%)	15(51.72%)	<0.001
Yes	75(19.43%)	14(48.28%)	
Diabetes			
No	359(93.01%)	23(79.31%)	0.009
Yes	27(6.99%)	6(20.69%)	
AIDS			
No	385(99.74%)	29(100%)	0.784
Yes	1(0.26%)	0(0%)	
HBV			
No	366(94.82%)	27(93.1%)	0.691
Yes	20(5.18%)	2(6.9%)	
CHD			
No	362(93.78%)	14(48.28%)	<0.001
Yes	24(6.22%)	15(51.72%)	
FLD			
No	325(84.2%)	18(62.07%)	0.002
Yes	61(15.8%)	11(37.93%)	
Smoking history, n (%)			
No	368(95.34%)	26(89.66%)	0.179
Yes	18(4.66%)	3(10.34%)	
Drinking history, n (%)			
No	374(96.89%)	27(93.1%)	0.276
Yes	12(3.11%)	2(6.9%)	
CT evidence of pneumonia			
No	328(84.97%)	26(89.66%)	0.493
Yes	58(15.03%)	3(10.34%)	

Supportive treatment, n (%)			
Administration of antiviral medications			
No	59(15.28%)	1(3.45%)	0.081
Yes	327(84.72%)	28(96.55%)	
Administration of interferon atomization			
No	286(74.09%)	10(34.48%)	<0.001
Yes	100(25.91%)	19(65.52%)	
Administration of antibiotics			
No	288(74.61%)	0(0%)	<0.001
Yes	98(25.39%)	29(100%)	
Administration of systemic corticosteroids			
No	364(94.3%)	3(10.34%)	<0.001
Yes	22(5.7%)	26(89.66%)	
Use of blood products			
No	367(95.08%)	4(13.79%)	<0.001
Yes	19(4.92%)	25(86.21%)	
Use of low molecular weight heparin			
No	368(95.34%)	4(13.79%)	<0.001
Yes	18(4.66%)	25(86.21%)	
Use of sedative			
No	351(90.93%)	12(41.38%)	<0.001
Yes	35(9.07%)	17(58.62%)	
Virus clearance (Intestinal later than respiratory)			
No	371(96.11%)	29(100%)	0.28
Yes	15(3.89%)	0(0%)	

241 Abbreviation: AIDS, Acquired Immune Deficiency Syndrome; HBV, hepatitis B
 242 virus; CHD, Coronary Heart Disease; FLD, Fatty Liver Disease.

243

244

245

246

247

248

249

250

251

252

253

Table 3. Laboratory Findings of Patients with COVID-19

254

Laboratory Finding	Patients with non-severe COVID-19(n=321)	Patients with severe COVID-19(n=27)	P value
Leukocyte count, $\times 10^9$ cells/L	4.68(3.73-5.66)	6.24(4.47-7.74)	0.082
Neutrophil, %	63.29 \pm 11.44	72.48 \pm 13.70	0.001
Neutrophil count, $\times 10^9$ cells/L	2.85(2.28-3.79)	4.06(3.26-6.42)	0.004
Lymphocyte, %	24.50(20.6-31.9)	15.5(5.9-21.6)	<0.001
Lymphocyte count, $\times 10^9$ cells/L	1.12(0.82-1.49)	0.88(0.45-1.22)	0.001
Monocyte, %	9.5(7.3-11.3)	7.2(4.0-13.6)	0.015
Monocyte count, $\times 10^9$ cells/L	0.41(0.35-0.58)	0.50(0.24-1.07)	0.157
Hemoglobin level, g/L	138.29 \pm 16.15	129.86 \pm 29.99	0.017
Hematokrit, %	40.21 \pm 4.35	38.92 \pm 4.20	0.143
Platelet count, $\times 10^9$ cells/L	177(143-220)	155(117-189.5)	0.455
C-reactive protein level, mg/L	6.06(0.499-18.45)	70.74(31.02-103.77)	<0.001
ESR, mm/60min	48(25-89)	82(42.5-110.5)	0.027
Prothrombin time, s	13.5(13.0-13.8)	13.9(12.85-15.55)	0.266
FDP	0.88(0.39-1.47)	2.42(1.29-20.25)	0.006
D-dimer	0.43(0.24-0.57)	0.89(0.57-5.26)	<0.001
BNP	29.41(21.05-46.28)	133.30(56.38-504.4)	0.005
Procalcitonin, ng/mL	0.03(0.02-0.05)	0.14(0.07-0.35)	<0.001
Alanine aminotransferase level, U/L	20(14-34)	25(14-37)	0.289
Albumin level, g/L	41.71 \pm 4.59	36.61 \pm 5.94	<0.001
Globulin level, g/L	28.22(25.9-30.91)	27.95(25.22-31.35)	0.06
Creatinine	64.48(51.73-74.36)	66.87(56.30-80.93)	0.149
eGFR	112.16(95.74-131.56)	99.70(81.31-117.08)	0.166
CK-MB	11.31(9.68-15.13)	14.42(10.86-20.58)	0.003
Total bilirubin level, mmol/L [mg/dL]	8.2(6.3-13.8)	10.3(6.95-15.0)	0.049
Lactate, mmol/L	2.67(2.31-3.07)	2.50(2.31-3.64)	0.534
Lactate dehydrogenase level, U/L	214(190-268)	399(278-537)	<0.001
NLR	2.67(1.76-3.42)	4.16(3.14-14.65)	<0.001
LMR	2.73(1.84-3.66)	1.92(0.51-3.13)	0.052
PLR	145.64(119.87-196.68)	180.68(110.56-457.96)	0.004

255

256

257

258

259

260

Table 4. Laboratory Findings of Patients with COVID-19

Laboratory Finding	Patients with non-severe COVID-19(n=321)	Patients with severe COVID-19(n=27)	P value
Lactate dehydrogenase level, U/L			
≤290.5	315(81.82%)	10(34.48%)	<0.001
>290.5	70(18.18%)	19(65.52%)	
NLR			
≤3.5	289(74.87%)	8(27.59%)	<0.001
>3.5	97(25.13%)	21(72.41%)	
LMR			
≤3.0	209(54.15%)	19(65.52%)	0.236
>3.0	177(45.85%)	10(34.48%)	
PLR			
≤222.5	318(82.38%)	15(51.72%)	<0.001
>222.5	68(17.62%)	14(48.28%)	

261


262

Table 5. Risk factors for severe cases

263


Variables	P	OR	95% CI for OR	
			Lower	Upper
Diabetes	0.028	15.824	1.338	187.186
FLD	0.007	21.469	2.306	199.872
CHD	0.009	18.157	2.085	158.083
NLR	0.031	1.729	1.050	2.847
ESR	0.043	0.969	0.940	0.999

264



265
266
267
268
269

Fig. 1 The cut-off values for the inflammation-related parameters. A-D. ROC curves were adopted to calculate the cut-off values for LDH(A), NLR (B), LMR (C), and PLR(D). LDH, lactate dehydrogenase, NLR, neutrophil-to-lymphocyte ratio, LMR, lymphocyte-to-monocyte ratio, PLR, platelet-to-lymphocyte ratio, AUC, area of under curve.



270
271
272
273

Fig. 2 The combined predictive indicator and other risk factors for ROC curves. NLR, neutrophil-to-lymphocyte ratio, ESR, erythrocyte sedimentation rate.

274 **References**

- 275 1. Chang, et al., *Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections*
276 *Involving 13 Patients Outside Wuhan, China*. JAMA, 2020.
- 277 2. Chen, N., et al., *Epidemiological and clinical characteristics of 99 cases of 2019 novel*
278 *coronavirus pneumonia in Wuhan, China: a descriptive study*. Lancet, 2020. **395**(10223): p.
279 507-513.
- 280 3. Li, Q., et al., *Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected*
281 *Pneumonia*. N Engl J Med, 2020.
- 282 4. Zhu, N., et al., *A Novel Coronavirus from Patients with Pneumonia in China, 2019*. N Engl J
283 Med, 2020. **382**(8): p. 727-733.
- 284 5. Gasparyan, A.Y., et al., *The Platelet-to-Lymphocyte Ratio as an Inflammatory Marker in*
285 *Rheumatic Diseases*. Ann Lab Med, 2019. **39**(4): p. 345-357.
- 286 6. Ha, Y.J., et al., *Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict*
287 *survival in patients with adult polymyositis and dermatomyositis: A retrospective*
288 *observational study*. PLoS One, 2018. **13**(1): p. e0190411.
- 289 7. Ying, H.Q., et al., *The prognostic value of preoperative NLR, d-NLR, PLR and LMR for*
290 *predicting clinical outcome in surgical colorectal cancer patients*. Med Oncol, 2014. **31**(12): p.
291 305.
- 292 8. Liu, Y., et al., *Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in*
293 *hospitalized patients with COVID-19*. J Infect, 2020.
- 294 9. Qin, C., et al., *Dysregulation of immune response in patients with COVID-19 in Wuhan, China*.
295 Clin Infect Dis, 2020.
- 296 10. Li, X., et al., *Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan*. J
297 Allergy Clin Immunol, 2020.
- 298 11. Chen, G., et al., *Clinical and immunologic features in severe and moderate Coronavirus*
299 *Disease 2019*. J Clin Invest, 2020.
- 300 12. Tian, S., et al., *Characteristics of COVID-19 infection in Beijing*. J Infect, 2020. **80**(4): p.
301 401-406.
- 302 13. Huang, C., et al., *Clinical features of patients infected with 2019 novel coronavirus in Wuhan,*
303 *China*. Lancet, 2020. **395**(10223): p. 497-506.
- 304 14. Corman, V.M., et al., *SARS-CoV-2 asymptomatic and symptomatic patients and risk for*
305 *transfusion transmission*. Transfusion, 2020.
- 306 15. Hu, Z., et al., *Clinical characteristics of 24 asymptomatic infections with COVID-19 screened*
307 *among close contacts in Nanjing, China*. Sci China Life Sci, 2020. **63**(5): p. 706-711.
- 308 16. Chan, J.F., et al., *A familial cluster of pneumonia associated with the 2019 novel coronavirus*
309 *indicating person-to-person transmission: a study of a family cluster*. Lancet, 2020.
310 **395**(10223): p. 514-523.
- 311 17. Lan, L., et al., *Positive RT-PCR Test Results in Patients Recovered From COVID-19*. JAMA,
312 2020.
- 313 18. Flint, S.W. and A.A. Tahrani, *COVID-19 and obesity-lack of clarity, guidance, and*
314 *implications for care*. Lancet Diabetes Endocrinol, 2020.
- 315 19. Yu, J., et al., *SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in*
316 *Wuhan, China*. JAMA Oncol, 2020.

317